Nectin-4-targeting dexabody

Nectin-4-targeting dexabody is a preclinical-stage therapeutic candidate developed by Dextera Biosciences for the treatment of various oncology indications. The drug utilizes Dextera's proprietary "dexabody" platform, which consists of synthetic D-proteins—mirror-image versions of natural L-proteins designed for enhanced stability against proteolytic degradation and reduced immunogenicity. This specific asset is a payload conjugate, functioning as a peptide-drug conjugate (PDC) that targets Nectin-4 (Poliovirus receptor-related protein 4), a cell surface protein frequently overexpressed in several solid tumors, including bladder, breast, and lung cancers. By binding to Nectin-4, the dexabody delivers a conjugated cytotoxic payload directly to the tumor cells to induce cell death while minimizing off-target effects.